{"task_id": "65f6da60159b308b", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 210/464)", "text": "\nHereditary Cancers (p. 224)\nColorectal Cancer\n199\n\n--- Page 221 ---\nMANAGEMENT OF RECTAL CANCER\nHIGHLY RESECTABLE (stage I)\ntransanal exci\nsion\nonly\nif\n<30%\ncircumference,\n<3\ncm\n[<1.2 in.], margins >0.3 cm [>0.12 in.] mobile,\nwithin 8 cm [3.1 in.] of anal verge, no lymphovascu\nlar or perineural invasion, well or moderately differ\nentiated tumor. Otherwise, total mesorectal exci\nsion via low anterior resection or abdominoperineal\nresection\nRESECTABLE (stage II and some stage III with no high\nrisk feature (not fixed, not low <5 cm [2 in.], not\nbulky)\nneoadjuvant radiation (short course, 1\nweek) + total mesorectal excision + adjuvant che\nmotherapy based on pathologic stage: FOLFOX\u000312 if\npathologic node positive (i.e. node positive); capecita\nbine \u00038 if pathologic node negative. The type and the\nnumber of cycles of adjuvant chemotherapy are, how\never, not well established. Local guideline may vary.\nNeoadjuvant chemoradiation is also an appropriate\noption for these patients\nPOSSIBLY RESECTABLE (locally advanced disease,\nparticularly if tethered to rectum or low lying tumor\n<5 cm [<2 in.] from anus)\nneoadjuvant chemor\nadiation (long course, 5 weeks, 5040 cGy plus infu\nsional 5 fluorouracil or capecitabine) + total mesor\nectal excision + adjuvant chemotherapy for 4\nmonths. Capecitabine or FOLFOX may be considered\ndepending on the extent of downstaging with\nneoadjuvant chemoradiation and the pathologic\nstage\nMETASTATIC (stage IV)\nsee management for stage\nIV colon cancer\n*NOTE: FOLFOX=5 fluorouracil, leucovorin, and oxa\nliplatin; FOLFIRI=5 fluorouracil, leucovorin, and iri\nnotecan;\n5 fluorouracil/LV=5 fluorouracil\nand\nleucovorin\nTREATMENT ISSUES\nESTIMATED BENEFITS OF ADJUVANT\nCHEMOTHERAPY FOR STAGE III COLORECTAL\nCANCER\nRELATIVE RISK REDUCTION FROM MAYO CLINIC\nDATABASE\nRecurrence\nDeath\n5 FU vs. control\nNode ve\n17%\n14%\nNode +ve\n40%\n34%\nTREATMENT ISSUES (CONT\u2019D)\nRecurrence\nDeath\nFOLFOX vs. 5 FU\nNode ve\n18%\n18%\nNode +ve\n24%\n24%\nRELATIVE RISK REDUCTION FROM ADJUVANT\nONLINE\nRecurrence\nDeath\n5 FU benefit\nNode ve\n20%\n18%\nNode +ve\n43%\n38%\nFOLFOX benefit\nNode ve\n39%\n24%\nNode +ve\n59%\n48%\nCOLORECTAL CANCER SURVEILLANCE\nfor patients\nwith stage II and III disease who would be candidate\nfor salvage treatment if recurrence, ASCO suggests\nmedical visit with history and physical examination\nevery 3 6 months \u00033 years, then every 6 months\nfor the next 2 years, and then yearly after. Perform\nCEA every 3 months for at least 3 years. CT chest/abd\n(+ CT pelvis for rectal cancer) yearly \u00033 years. Colono\nscopy 3 years after initial diagnostic colonoscopy,\nthen every 5 years. Proctosigmoidoscopy every\n6 months for 5 years if rectal cancer but radiation\nnot given\nMODULATORS OF 5 FLUOROURACIL ACTIVITY\nleucovorin (LV) promotes formation of a stable tern\nary complex with thymidylate synthetase, permit\nting prolonged inhibition of the enzyme by 5\nfluorouracil\nLIVER RESECTION CRITERIA\n\u0002\nRESECTABLE DISEASE\ninvolvement of <70% of liver\nand <6 segments, no involvement of major ves\nsels including SMA, SMV, hepatic vein, hepatic\nartery, portal vein, and no metastases elsewhere.\nAn evaluation by a hepatobiliary surgeon should\nalways be considered\n\u0002\nOPERABLE CANDIDATE\nrelatively young, no major\ncomorbidities, performance status 0 1\n\u0002\nPREDICTIVE\nFACTORS\nOF\nRECURRENCE\nPOST-LIVER\nMETASTASECTOMY\ntumor >5 cm [>2 in.], >1\nliver lesion, lymph node involvement, relapse\nfree survival <1 year, CEA >200 mg/L within 1\nmonth post surgery\n200\nColorectal Cancer", "text_length": 3463, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 210/464)", "type": "chunk", "chunk_index": 209, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.535262", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.536314", "status": "complete", "chunks_added": 2}